Acknowledgements Learning objectives Privacy Policy Cookie Policy How Can We Help?
ECCO 2024 Medfyle Conference Coverage
Available on the Medfyle App

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM LILLY

Welcome to Medfyle

ECCO 2024 Conference Coverage!

Your selection of highlights and key takeaways from the ECCO Congress 2024.

Edouard Louis, MD, PhD 

ECCO 2024 Medfyle Conference Coverage Editor

Interviews

Want to see more interviews?
See all

Oral presentations

Missed the full presentation? Read at-a-glance summaries from a selection of oral and digital oral presentations. Don’t forget to download the slides!

Crohn's Disease

CONFIDE: bowel urgency in CD

Bowel urgency is a distressing symptom that has a major impact on people’s lives. New data from CONFIDE show the extent of the problem in Crohn’s disease, with over one-third reporting bowel urgency – suggesting a significant burden and impact that should be addressed.

ECCO 2024 - Oral session 

CONFIDE: Communicating the prevalence and severity of bowel urgency in CD

Read more

01-confide-bowel-urgency-in-cd
Crohn's Disease

Mirikizumab in CD

In the VIVID-1 treat-through study, a series of patient-reported outcomes were collected, looking at key symptoms and quality of life throughout the trial. Results showed improvements in fatigue, bowel urgency, and health-related quality of life, plus across composite endpoints.

ECCO 2024 - Oral session 

VIVID RCT: Fatigue, bowel urgency, and QoL improved with mirikizumab in moderate-to-severely active CD

Read more

02-mirikizumab-in-cd
Ulcerative colitis

TRIUMPH: Tofacitinib in ASUC

ASUC affects up to 25% of people with UC, and time to response is critical. Current treatment options are limited, but there could be a place for tofacitinib. New data from TRIUMPH explore clinical response, with favorable results.

ECCO 2024 - Oral session 

TRIUMPH: Tofacitinib in patients hospitalized with ASUC

Read more

03-triumph-tofacitinib-in-asuc
See More

Posters

Read at-a-glance summaries from a selection of poster presentations.

Ulcerative colitis

CONFIDE: Bowel urgency in UC

The CONFIDE survey has collected experiences of bowel urgency across IBD patients and geographies. Now the latest data show the prevalence and impact of this symptom in UC, and support the idea of evaluating and treating this common symptom to help improve quality of life.

ECCO 2024 - Poster session

CONFIDE: comparisons of bowel urgency experiences in UC patients in Canada, Europe, and the US – a descriptive survey

Read more

p01-confide-bowel-urgency-in-uc
Ulcerative colitis

LUCENT: Mirikizumab extended induction

Not all patients respond to induction by Week 12, but extended induction could give incremental improvements over time in early non-responders. New data from LUCENT look at extended induction across a range of clinical and symptomatic outcomes.

ECCO 2024 - Poster session

LUCENT-1 and -2: Extended induction response with mirikizumab over time in UC

Read more

p02-lucent-mirikizumab-extended-induction
Ulcerative colitis

Mucosal healing and UC burden

STRIDE II considers disability-free and normal quality of life as therapeutic targets. But the degree of mucosal healing required to reduce disability, incontinence, and bowel urgency is unknown. This cross-sectional study examines the depth of mucosal healing on the disease burden.

ECCO 2024 - Poster session

A cross-sectional study to reveal the impact of depth of mucosal healing on UC burden

Read more

p03-mucosal-healing-and-uc-burden
See More

Deep Dive

Watch on-demand videos, led by experts, to dive deeper into subjects of special interest.

Feedback

Want more gastroenterology content?

Subscribe to the Medfyle Newsletter and receive:
  • The ECCO 2024 Congress key highlights slide kit
  • Access to the latest news from international conferences
  • Bite-sized summaries of practice-changing publications

Ask the Expert

Have a question? Submit it below.
A selection of the most interesting questions will be answered in a new video. You will receive an email when answers will be published.